India's Biocon Biologics says biosimilars put revenue on $1 billion trajectory

India's Biocon Biologics says biosimilars put revenue on $1 billion trajectory Biocon Biologics, which acquired the biosimilars business of US-based Viatris in a $3.34 billion deal, informed its annual revenue rose 61 per cent year-on-year to 55.84 billion rupees, reflecting one quarter of consolidated figures after the buy, compared to 34.64 billion rupees the previous year. https://ift.tt/Evr0lIk